AstraZeneca could face limited fallout from Chinese tax probe 逃稅風(fēng)波下 阿斯利康中國營收仍創(chuàng)新高
The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank 事件的主角之一，很可能是此前因“配合調(diào)查”而消失于公眾視野的阿斯利康前中國區(qū)總裁王磊。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.